Patent number: 9433621
Abstract: The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.
Type:
Grant
Filed:
February 18, 2011
Date of Patent:
September 6, 2016
Assignees:
Merck Sharp & Dohme Corp., Southern Research Institute
Inventors:
Ashok Arasappan, F. George Njoroge, Cecil D. Kwong, Subramaniam Ananthan, Frank Bennett, Francisco Velazquez, Vinay M. Girijavallabhan, Yuhua Huang, Hollis S. Kezar, III, Joseph A. Maddry, Robert C. Reynolds, Abhijit Roychowdhury, Anita T. Fowler, John A. Secrist, III, Joseph A. Kozlowski, Bandarpalle B. Shankar, Ling Tong, Seong Heon Kim, Malcolm MacCoss, Srikanth Venkatraman, Vishal Verma
Publication number: 20140242027
Abstract: The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.
Type:
Application
Filed:
February 18, 2011
Publication date:
August 28, 2014
Applicants:
Southern Research Institute, Merck Sharp & Dohne Corp.
Inventors:
Ashok Arasappan, F. George Njoroge, Cecil D. Kwong, Subramaniam Ananthan, Frank Bennett, Francisco Velazquez, Vinay Girijavallabhan, Yuhua Huang, Hollis S. Kezer, Joseph Maddry, Robert C. REynold, Abhijit Roychowdhury, Anita T. Fowler, John A. Secrist, III, Ling Tong, Seong Heon Kim, Malcolm MacCoss, Srikanth Venkatraman, vishal Verma
Patent number: 8697694
Abstract: The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.
Type:
Grant
Filed:
August 19, 2009
Date of Patent:
April 15, 2014
Assignees:
Merck Sharp & Dohme Corp., Southern Research Institute
Inventors:
Ashok Arasappan, F. George Njoroge, Cecil D. Kwong, Subramaniam Ananthan, Frank Bennett, Jeremy Clark, Hollis S. Kezar, III, Vinay M. Girijavallabhan, Yuhua Huang, Regina Huelgas, Joseph A. Maddry, John J. Piwinski, Robert C. Reynolds, Abhijit Roychowdhury, Anita T. Fowler, Feng Geng, John A. Secrist, III, Neng-Yang Shih, Vishal Verma, Francisco Velazquez, Srikanth Venkatraman
